Evaluation of HPV Molecular Tests in Primary Screening for Cervical Cancer in Brazil

DOI: 10.4236/ojog.2014.48068   PDF   HTML   XML   6,431 Downloads   8,121 Views   Citations


Background: Incorporation of HPV tests into cervical cancer screening programs may be advantageous over conventional cytology, especially in developing nations, where the largest burden of cervical cancer is observed. Objectives: To conduct an evaluation of commercially available molecular HPV tests in Brazilian women. Study design: Two groups were recruited: group A was composed of 511 women referred to the clinics because of a previous abnormal Pap test while group B consisted of 2464 subjects under routine screening. Cervical samples were collected using SurePath liquid cytology (LBC) device, and split into aliquots which were submitted to molecular testing by Hybrid Capture and cobas HPV. Colposcopy and biopsies were made according to the standard guidelines, directed by cytological diagnosis. Results: Prevalence of HSIL was 5.97% and 0.7% in Group A and B respectively. High-Risk HPV DNA was found in about 9% of group B women, while in group A this frequency was 24%. Having CIN3+ as the study end-point, the negative predictive values for molecular methods were above 99.8%. All “in-situ” and invasive cervical carcinomas were detected by both HPV nucleic acid assays. Conclusion: Use of HPV DNA testing was feasible and highly sensitive in cancer screening settings of Brazil.

Share and Cite:

Levi, J. , Longatto-Filho, A. , Eluf-Neto, J. , Rodrigues, C. , Oliveira, C. , Carloni, A. , Lorenzi, A. , Tacla, M. , Fregnani, J. , Ab’Saber, A. , Scapulatempo, C. and Villa, L. (2014) Evaluation of HPV Molecular Tests in Primary Screening for Cervical Cancer in Brazil. Open Journal of Obstetrics and Gynecology, 4, 470-478. doi: 10.4236/ojog.2014.48068.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Franco, E.L., Rohan, T.E. and Villa, L.L. (1999) Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer. Journal of the National Cancer Institute, 17, 506-511. http://dx.doi.org/10.1093/jnci/91.6.506
[2] Zur Hausen, H. (2002) Papillomaviruses and Cancer: From Basic Studies to Clinical Application. Nature Reviews Cancer, 2, 342-350. http://dx.doi.org/10.1038/nrc798
[3] Mayrand, M.H., Duarte-Franco, E., Rodrigues, I., Walter, S.D., Hanley, J., Ferenczy, A., Ratnam, S., Coutlée, F. and Franco, E.L. (2007) Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. The New England Journal of Medicine, 357, 1579-1588. http://dx.doi.org/10.1056/NEJMoa071430
[4] Roth, W.K., Busch, M.P., Schuller, A., Ismay, S., Cheng, A., Seed, C.R., et al. (2012) International Survey on NAT Testing of Blood Donations: Expanding Implementation and Yield from 1999 to 2009. Vox Sanguinis, 102, 82-90. http://dx.doi.org/10.1111/j.1423-0410.2011.01506.x
[5] Saslow, D., Solomon, D., Lawson, H.W., et al. (2012) American Cancer Society, American Society for Colposcopyand Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the Prevention and Early Detection of Cervical Cancer. American Journal of Clinical Pathology, 137, 516-542. http://dx.doi.org/10.1309/AJCPTGD94EVRSJCG
[6] Naucler, P., Ryd, W., Tornberg, S., et al. (2007) Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer. The New England Journal of Medicine, 357, 1589-1597.
[7] Bulkmans, N., Berkhof, J., Rozendaal, L., et al. (2007) Human Papillomavirus DNA Testing for the Detection of Cervical Intraepithelial Neoplasia Grade 3 and Cancer: 5-Year Follow-Up of a Randomised Controlled Implementation Trial. Lancet, 370, 796-802.
[8] Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., et al. (2010) Efficacy of Human Papillomavirus Testing for the Detection of Invasive Cervical Cancers and Cervical Intraepithelial Neoplasia: A Randomised Controlled Trial. The Lancet Oncology, 11, 249-257. http://dx.doi.org/10.1016/S1470-2045(09)70360-2
[9] Schiffman, M., Wentzensen, N., Wacholder, S., Kinney, W., Gage, J.C. and Castle, P.E. (2011) Human Papillomavirus Testing in the Prevention of Cervical Cancer. Journal of the National Cancer Institute, 103, 368-383. http://dx.doi.org/10.1093/jnci/djq562
[10] Mühlberger, N., Sroczynski, G., Esteban, E., Mittendorf, T., Miksad, R.A. and Siebert, U. (2008) Cost-Effectiveness of Primarily Human Papillomavirus-Based Cervical Cancer Screening in Settings with Currently Established Pap Screening: A Systematic Review Commissioned by the German Federal Ministry of Health. The International Journal of Technology Assessment in Health Care, 24, 184-192. http://dx.doi.org/10.1017/S0266462308080264
[11] Levin, C.E., Sellors, J., Shi, J.F., Ma, L., Qiao, Y.L., Ortendahl, J., et al. (2010) Cost-Effectiveness Analysis of Cervical Cancer Prevention Based on a Rapid Human Papillomavirus Screening Test in a High-Risk Region of China. International Journal of Cancer, 127, 1404-1411.
[12] Vijayaraghavan, A., Efrusy, M., Lindeque, G., Dreyer, G. and Santas, C. (2009) Cost Effectiveness of High-Risk HPV DNA Testing for Cervical Cancer Screening in South Africa. Gynecologic Oncology, 112, 377-383. http://dx.doi.org/10.1016/j.ygyno.2008.08.030
[13] Flores, Y.N., Bishai, D.M., Lorincz, A., Shah, K.V., Lazcano-Ponce, E., Hernández, M., Granados-García, V., Pérez, R. and Salmerón, J. (2011) HPV Testing for Cervical Cancer Screening Appears More Cost-Effective than Papanicolaou cytology in Mexico. Cancer Causes Control, 22, 261-272.
[14] Berkhof, J., Coupé, V.M., Bogaards, J.A., van Kemenade, F.J., Helmerhorst, T.J., Snijders, P.J. and Meijer, C.J. (2010) The Health and Economic Effects of HPV DNA Screening in The Netherlands. International Journal of Cancer, 127, 2147-2158. http://dx.doi.org/10.1002/ijc.25211
[15] Rijkaart, D.C., Berkhof, J., van Kemenade, F.J., Coupe, V.M., Hesselink, A.T., Rozendaal, L., et al. (2012) Evaluation of 14 Triage Strategies for HPV DNA-Positive Women in Population-Based Cervical Screening. International Journal of Cancer, 130, 602-610. http://dx.doi.org/10.1002/ijc.26056
[16] Rijkaart, D.C., Berkhof, J., Rozendaal, L., van Kemenade, F.J., Bulkmans, N.W., Heideman, D.A., et al. (2012) Human Papillomavirus Testing for the Detection of High-Grade Cervical Intraepithelial Neoplasia and Cancer: Final Results of the POBASCAM Randomised Controlled Trial. The Lancet Oncology, 13, 78-88. http://dx.doi.org/10.1016/S1470-2045(11)70296-0
[17] Lazcano-Ponce, E. and Allen-Leigh, B. (2009) Innovation in Cervical Cancer Prevention and Control in Mexico. Archives of Medical Research, 40, 486-492. http://dx.doi.org/10.1016/j.arcmed.2009.07.007
[18] Silva, G.A., Gamarra, C.J., Girianelli, V.R. and Valente, J.G. (2011) Cancer Mortality Trends in Brazilian State Capitals and Other Municipalities between 1980 and 2006. Revista de Saúde Pública, 45, 1009-1018. http://dx.doi.org/10.1590/S0034-89102011005000076
[19] Cancer Incidence in Brazil (2011) Estimate for Year 2012/ Instituto Nacional de Cancer José Alencar Gomes da Silva, Coordenacao Geral de Acoes Estratégicas, Coordenacao de Prevencao e Vigilancia, Rio de Janeiro. http://www.inca.gov.br?
[20] Gravitt, P.E., Belinson, J.L., Salmeron, J. and Shah, K.V. (2011) Looking Ahead: A Case for Human Papillomavirus Testing of Self-Sampled Vaginal Specimens as a Cervical Cancer Screening Strategy. International Journal of Cancer, 129, 517-527. http://dx.doi.org/10.1002/ijc.25974
[21] Fregnani, J.H., Scapulatempo, C., Haikel, Jr., R.L., Saccheto, T., Campacci, N., Mauad, E.C., Longatto-Filho, A., RODEO Study Team (2013) Could Alarmingly High Rates of Negative Diagnoses in Remote Rural Areas Be Mini-mized with Liquid-Based Cytology? Preliminary Results from the RODEO Study Team. Acta Cytologica, 57, 69-74. http://dx.doi.org/10.1159/000343046
[22] Newcombe, R.G. (1998) Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statistics in Medicine, 17, 857-872.
[23] Villa, L.L. (2008) Assessment of New Technologies for Cervical Cancer Screening. The Lancet Oncology, 9, 910-911. http://dx.doi.org/10.1016/S1470-2045(08)70238-9
[24] Arbyn, M., Ronco, G., Meijer, C.J. and Naucler, P. (2009) Trials Comparing Cytology with Human Papillomavirus Screening. The Lancet Oncology, 10, 935-936. http://dx.doi.org/10.1016/S1470-2045(09)70296-7
[25] Leinonen, M., Nieminen, P., Kotaniemi-Talonen, L., Malila, N., Tarkkanen, J., Laurila, P. and Anttila, A (2009) AgeSpecific Evaluation of Primary Human Papillomavirus Screening vs Conventional Cytology in a Randomized Setting. Journal of the National Cancer Institute, 101, 1612-1623.
[26] Heideman, D.A., Hesselink, A.T., Berkhof, J., van Kemenade, F., Melchers, W.J., Daalmeijer, N.F., et al. (2011) Clinical Validation of the Cobas 4800 HPV Test for Cervical Screening Purposes. Journal of Clinical Microbiolog, 49, 3983-3985. http://dx.doi.org/10.1128/JCM.05552-11
[27] Meijer, C.J., Berkhof, J., Castle, P.E., Hesselink, A.T., Franco, E.L., Ronco, G., et al. (2009) Guidelines for Human Papillomavirus DNA Test Requirements for Primary Cervical Cancer Screening in Women 30 Years and Older. International Journal of Cancer, 124, 516-520. http://dx.doi.org/10.1002/ijc.24010
[28] Ayres, A.R. and Silva, G.A. (2010) Cervical HPV Infection in Brazil: Systematic Review. Revista de Saúde Pública, 44, 963-974.
[29] Schlecht, N.F., Platt, R.W., Duarte-Franco, E., Costa, M.C., Sobrinho, J.P., Prado, J.C., et al. (2003) Human Papillomavirus Infection and Time to Progression and Regression of Cervical Intraepithelial Neoplasia. Journal of the National Cancer Institute, 95, 1336-1343.
[30] Schopp, B., Holz, B., Zago, M., Stubenrauch, F., Petry, K.U., Kjaer, S.K. and Iftner, T. (2010) Evaluation of the Performance of the Novel Papillo Check HPV Genotyping Test by Comparison with Two Other Genotyping Systems and the HC2 Test. Journal of Medical Virology, 82, 605-615.
[31] Wright, Jr., T.C., Stoler, M.H., Sharma, A., Zhang, G., Behrens, C., Wright, T.L., ATHENA (Addressing the Need for Advanced HPV Diagnostics) Study Group (2011) Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women with High-Risk HPV+ Cytology-Negative Results. American Journal of Clinical Pathology, 136, 578-586. http://dx.doi.org/10.1309/AJCPTUS5EXAS6DKZ

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.